Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2018
NCT03745885
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

metformin (glucophage) (1 trial)

supaglutide (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2